Navigation Links
Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Date:12/17/2007

EDMONTON, Dec. 17 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX Venture Exchange: QPT) today announced that it has signed an agreement with a multinational technology development company (the "Investor") to receive $3,000,000 to develop oncology products based on its SonoLight Technology. Under the terms of the agreement, Quest Pharma Tech Inc. ("Quest" or the "Company") has already received $1,000,000; and the balance of $2,000,000 will be paid within the next twelve months. In return for this non-equity funding, the Investor who requested to remain anonymous, will receive 35 percent of all future net revenue from the commercialization of Quest's oncology products. This agreement does not preclude Quest from out-licensing the oncology applications of SonoLight Technology to a third party.

The Company's lead oncology product from the SonoLight platform, SL052, is anticipated to enter a Phase I clinical trial for photodynamic therapy treatment of prostate cancer during the second half of 2008. The Company is also evaluating the same technology for the treatment of lung cancer and peritoneal carcinomatosis.

"I can't think of a better holiday present to our shareholders than establishing an accelerated oncology development program," said Dr. Madi R. Madiyalakan, Chief Executive Officer of Quest Pharma Tech Inc. "We are optimistic about the potential of both our oncology products and our dermatology program. Additionally, we believe that our partnerships with Paramount BioSciences and KMH Co. Ltd. will help us achieve our long-term growth objectives, including share price appreciation."

About Quest PharmaTech Inc.

The Corporation is a publicly traded (TSX Venture Exchange: QPT), Alberta-based pharmaceutical company committed to build shareholder value through discovery, development, and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... This is a professional and in-depth study ... industry in Global and China. The report provides a ... industry chain structure. Global market analysis and Chinese domestic ... developments, trends and competitive landscape of the market. A ... offered. , The report also focuses on development policies ...
(Date:9/22/2014)... , Sept. 22, 2014 Research ... "Global and Chinese Microcrystalline Cellulose Industry Report 2014" ... Global and Chinese Microcrystalline Cellulose Industry Report 2014 is ... of the global microcrystalline cellulose industry with a focus ... a basic overview of the industry including definitions, classifications, ...
(Date:9/22/2014)... N.J. , Sept. 22, 2014  WIRB-Copernicus ... and ethical review services for clinical research, announced ... (WIRB) has been reaccredited by the Association ... (AAHRPP), which endeavors to improve safeguards for clinical ... Donald A. Deieso , Ph.D., commented, "It ...
(Date:9/21/2014)... at the University of Basel in Switzerland have ... a charged molecule for the first time. These ... measurements of molecular properties and may also contribute ... technology. The results were published in the scientific ... study of the interaction between matter and light, ...
Breaking Biology Technology:m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 3Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Uncovering the forbidden side of molecules 2
... Inc. (OTC Bulletin Board: NWBO ) (NW Bio) joined ... over the course of more than 13 months, the parties ... brain cancer in Germany. As a result, the Company is ... with both its clinical trial program and Hospital Exemption cases ...
... J.D., will offer her expert perspective on  the ... she presents "EHRs: Meaningful Use & Beyond" during ... held  April 24-26, 2012, at the Thelma Keller ... During the presentation, Pita, who serves as executive ...
... facilitated the evolution and complexity of terrestrial organisms, including human ... by those organisms, which in turn were able to generate ... oxygen molecules work inside the body, more attention is being ... to thwart them. A number of environmental ...
Cached Biology Technology:Northwest Bio and Fraunhofer IZI Announce Milestones Reached 2Northwest Bio and Fraunhofer IZI Announce Milestones Reached 3Northwest Bio and Fraunhofer IZI Announce Milestones Reached 4Prognosis HIS Executive Slated To Offer EHR Advice At Illinois Rural Health Association Conference 2Avocado Oil: The 'Olive Oil Of The Americas'? 2Avocado Oil: The 'Olive Oil Of The Americas'? 3Avocado Oil: The 'Olive Oil Of The Americas'? 4
(Date:9/22/2014)... key molecular cog in a plant,s biological clock ... based on temperature. , Transcription factors, or genetic switches, ... such as light, rain, soil quality, or even ... USC has isolated one, called FBH1, that reacts to ... needed while in keeping it on a consistent track. ...
(Date:9/22/2014)... the Society of Environmental Toxicology and Chemistry (SETAC) held ... prioritize the scientific research needed to understand the risks ... environment. The effort was extended, and results were ... international journal, Integrated Environmental Assessment and Management ... podcast interviewing the lead author of the study, Murray ...
(Date:9/22/2014)... YORK CITY (September 22, 2014)The Brain & ... the award of NARSAD Young Investigator Grants ... 200 of the world,s most promising young ... for groundbreaking neurobiological research will seek to ... strategies for psychiatric disorders that affect one ...
Breaking Biology News(10 mins):Genetic switch regulates a plant's internal clock based on temperature 2Priorities for research on pharmaceutical and personal care products in the environment 2Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2
... new use as an adjuvant to cancer therapy, providing an ... study published in the Feb. 15 issue of Clinical Cancer ... Gallez, Ph.D., professor of pharmacy at the Université de Louvain ... A into two types of mouse tumors, the tumors' cellular ...
... H5N1 influenza samples in Southeast Asia shows not only ... are related but also that they belong to two ... for Disease Control and Prevention report their findings today ... "As the virus continues its geographic expansion, it is ...
... in Africa declared that a dramatic rise in tuberculosis (TB) ... TB case notifications have increased as much as four-fold over ... HIV. When individuals are infected with both HIV and TB, ... to active TB. , To combat the problem, the ...
Cached Biology News:Botox could help target resistant tumors for treatment 2Botox could help target resistant tumors for treatment 3Study outlines genetic differences between potential pandemic influenza strains 2
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Rabbit polyclonal to Xanthine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Xanthine Oxidase (from Bovine Buttermilk) Entrez Gene ID: 7498 Swiss Protein ID: P47989...
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Biology Products: